Coty Inc.

---

source: coverage-next-full step: 01 type: business_model ticker: COTY company: Coty Inc. generated: 2026-05-28

Step 01 — Business Model

Key Findings

• COTY operates a licensed-fragrance + mass-color hybrid business: ~63–65% of FY25 revenue comes from Prestige (license-heavy designer fragrance houses, plus owned prestige skincare); ~35–37% comes from Consumer Beauty (mass color cosmetics, mass fragrance, and Brazil) [S1][S3].
• The value-chain logic is asset-light at the brand-IP layer (Coty does not own most prestige brand IP; it licenses it from designer houses like Burberry, Hugo Boss, Gucci, Calvin Klein, and Marc Jacobs) but asset-heavy at the formulation + fragrance-creation + packaging + global distribution layer (Coty owns the perfumer relationships, contract-manufacturing relationships, and the global retail distribution network) [S3].
• The September 2025 strategic announcement explicitly integrates Prestige Beauty + Mass Fragrance into a single global Fragrance & Beauty unit, signaling that the next form factor of Coty is a fragrance-pure-play with skincare optionality — and that Consumer Beauty (mass color) is up for partnerships, divestitures, spin-offs, or other strategic alternatives [S2].
• Net: positive for thesis. The business model becomes more focused, more defensible, and structurally exposed to the fastest-growing beauty subsegment if Consumer Beauty is carved out.

Implications for Thesis and Valuation

• The fragrance license model is scale-dependent: economic moat comes from being the operating partner of choice for designer houses that lack in-house fragrance-creation, perfumer relationships, and global distribution. Coty's ability to renew Burberry (extended in 2023) and Hugo Boss (extended in 2024) is the single most important determinant of long-term enterprise value.
• The strategic-review optionality on Consumer Beauty is the largest near-term value-creation lever outside of license renewal. A successful divestiture would simplify the equity story toward an "Inter Parfums + scale" framing (~12–14x EV/EBITDA) versus the current ~7x multiple of the conglomerate.
• The owned-brand prestige skincare push (Lancaster, philosophy, Orveda — and possibly the SKKN/Kylie portfolio long term) is the optionality at the top end but is not yet scaled enough to materially move valuation.

Objective

Describe Coty's business model — what they sell, who they sell it to, and where they sit in the beauty value chain — so downstream steps on revenue architecture (Step 03), margin (Step 04), capital allocation (Step 07), and moat (Step 10) can build on a single coherent model.

Narrative Analysis

Two-segment structure

Prestige segment (~63% of FY25 revenue, ~65% in Q3 FY26) [S1][S3]:

• Licensed prestige fragrance houses: Burberry, Hugo Boss, Calvin Klein, Gucci, Marc Jacobs, Chloé, Davidoff, Jil Sander, Tiffany & Co., Joop!, Marni, Naomi Campbell (plus newer entries). Coty negotiates multi-decade licenses (typical structure: 10–20 years with renewal options), pays a royalty to the designer house, and controls the entire fragrance creation, manufacturing, marketing, and distribution stack [S3].
• Owned prestige brands: Lancaster, philosophy, Orveda (skincare); plus the Kylie / SKKN portfolio (license/partnership with Kim Kardashian and Kylie Jenner brands) — used as the platform for prestige skincare expansion.

Consumer Beauty segment (~37% of FY25, ~35% Q3 FY26) [S1][S3]:

• Mass color cosmetics: CoverGirl, Rimmel, Max Factor, Sally Hansen, Bourjois — mostly owned IP, distributed through drug, mass, and grocery channels.
• Mass fragrance: Adidas, Mexx, Coty-owned licensed mass fragrances — distributed through mass retail.
• Brazil portfolio: Risque, Monange, Paixao, Bozzano, Biocolor — local Brazilian brands acquired in 2012 from Hypermarcas; the largest player in Brazilian nail and locally relevant in fragrance/body. Approximately $400M of FY25 revenue [S2].

Value-chain map

Layer	Coty's role	Economics
Brand IP	Licensee for 80%+ of prestige fragrance	Pays royalty (typically MSD–HSD% of net sales) to designer house
Fragrance creation	Direct relationships with master perfumers + fragrance houses (Givaudan, Firmenich, IFF, Symrise)	Cost of goods item; Coty's scale gives it pricing power vs. peers
Packaging design / bottle	In-house creative + external design partners	Capex-light; mostly outsourced manufacturing
Manufacturing	Mix of owned (e.g., Sanford, NC; Granollers, Spain) + contract manufacturers	Capex ~3% of sales; lean footprint
Marketing	In-house brand management + agency partnerships	High-spend item: advertising / promotion typically 25–30% of net sales
Sales / distribution	Direct sales forces in major markets + distributor model in smaller markets	SG&A intensive
Retail	Selective distribution: department stores, sephora-class specialty, travel retail (prestige); mass retail + drug + grocery (consumer beauty); growing DTC + amazon	Retailer relationships are a competitive advantage

Revenue model

• Wholesale + retail mix: ~90%+ of revenue is wholesale to retailers (Macy's, Nordstrom, Sephora, Ulta in US; specialty + department stores internationally; mass retail for Consumer Beauty). DTC ecommerce share is growing but still a single-digit % of total revenue [S3].
• Travel retail: Material exposure (estimated 10%+ of prestige revenue), historically a high-margin channel; China travel-retail volatility was a meaningful 2024–2025 headwind [S3].
• Geographic split (FY25 approximate): EMEA largest at ~40%; Americas ~35% (US dominant); Asia-Pacific ~15%; Brazil/LatAm ~10% [S3].

The September 2025 reorganization

The "integrate Prestige + Mass Fragrance" announcement consolidates Coty's fragrance operations across price tiers into one operating engine — exploiting the fact that Coty is uniquely positioned as a top-2 player in both prestige fragrance (Burberry, Hugo Boss) and mass fragrance (Adidas, Mexx) [S2]. The thesis is that the perfumer-relationship, packaging-design, manufacturing-scale, and distribution advantages should be shared across price tiers rather than siloed.

The strategic review of Consumer Beauty (mass color + Brazil) explicitly evaluates partnerships, divestitures, spin-offs, and other actions. A spin-off would mirror what Procter & Gamble did with its beauty brands in 2016 (sold to Coty itself). A sale to a strategic (e.g., L'Oréal, Henkel) or a financial sponsor (KKR has appetite for beauty after acquiring Wella) are both plausible paths [S2].

Evidence and Sources

Detail in COTY_financials/sec_filings/10K_FY2025_summary.md and COTY_financials/presentations/investor_presentation_2025.md.

Assumption Register Updates

• A04 (Prestige ~63% of FY25 revenue) — Fact, High sensitivity (drives the segment-level valuation logic)

Tables and Calculations

Segment economic profile (FY25 illustrative, from 10-K disclosure)

Segment	Revenue	% of total	Reported segment profit (approx)	Margin (approx)	Notes
Prestige	~$3,700M	~63%	~$700M	~19%	Fragrance leadership drives margin
Consumer Beauty	~$2,190M	~37%	~$280M	~13%	Mass cosmetics softness pressures margin
Total reported	$5,892.9M	100%	~$980M (segment profit before corporate)	~17%	Reconciles to ~$1.08B adjusted EBITDA after corporate

(Approximations; exact segment profit varies by reported vs. adjusted basis. See COTY_financials/other/consensus.md for the company-reported adj. EBITDA of ~$1.08B at 18.4% margin.)

Brand portfolio at a glance

Tier	Brands	License vs Owned
Prestige fragrance — designer	Burberry, Hugo Boss, Calvin Klein, Gucci, Marc Jacobs, Chloé, Davidoff, Jil Sander, Tiffany & Co., Joop!, Marni, Naomi Campbell	Licensed
Prestige fragrance — owned	Lancaster heritage fragrance	Owned
Prestige skincare — owned	Lancaster, philosophy, Orveda	Owned
Prestige cosmetics — partnership	Kylie / SKKN portfolio	License/partnership
Mass color	CoverGirl, Rimmel, Max Factor, Sally Hansen, Bourjois	Owned
Mass fragrance	Adidas, Mexx, others	Mostly licensed
Brazil mass beauty	Risque, Monange, Paixao, Bozzano, Biocolor	Owned

Open Questions and Data Gaps

1. License expiry schedule. Coty does not publicly disclose a full schedule of remaining license terms. Step 10 (moat) will treat this as a key risk.
2. DTC ecommerce share growth. Disclosed only in passing; not quantified.
3. Per-brand revenue. Not disclosed below segment level except for marquee licenses.

Next-Step Dependencies

Step 02 will use the segment + geographic mix to size the addressable market by category. Step 03 will pull the quarterly segment trajectory.

Source Index

Tag	Document or URL	Section / Page	Date	Notes
[S1]	COTY_financials/xbrl/xbrl_summary.md	Annual + quarterly financials	2026-05-28	SEC XBRL
[S2]	COTY_financials/presentations/investor_presentation_2025.md	Strategic-review and segment narrative	2026-05-28	Coty press releases
[S3]	COTY_financials/sec_filings/10K_FY2025_summary.md	Business, segments, MD&A, brands	2025-08	Coty FY25 10-K, accession 0001024305-25-000030
[S4]	COTY_financials/industry/competitive_landscape.md	Peer + brand category positioning	2026-05-28	Multiple sources aggregated

Note: Earnings-call transcripts were intentionally not loaded (coverage-next-full path). Management commentary in this step is sourced from 8-K earnings releases (prepared-remarks summaries), press releases, and the FY25 10-K MD&A.

---

source: coverage-next-full step: 04 type: financial_quality ticker: COTY company: Coty Inc. generated: 2026-05-28

Step 04 — Financial Quality (incl. Adversarial Sweep)

Key Findings

• Earnings quality: medium. GAAP vs. adjusted divergence is sizable (FY25 GAAP net loss $367.9M vs. adj. EBITDA $1.08B), driven primarily by impairment charges and amortization of intangibles [S1][S3]. Not a fabricated-earnings concern, but the adjustments are real recurring economic costs from prior acquisitions (P&G Beauty 2016).
• Balance sheet quality: low–medium. Goodwill $4.06B + Intangibles ex-GW $3.21B = $7.28B, 61% of total assets [S1]. Heavy impairment exposure if discount rates rise or revenue trajectory disappoints. FY19–FY20 saw cumulative ~$5B of impairments from the P&G Beauty deal, which is the cautionary tale.
• Adversarial sweep: clean. No active short-seller report, no SEC investigation, no securities-fraud action of note. Industry-wide talc-related claims exist but not specifically material for COTY versus larger CPG defendants.
• Net: mixed. Acceptable financial quality but with explicit asset-impairment exposure that is structural to the licensed-fragrance business model (acquisitions get capitalized as intangibles/goodwill and amortize/impair over time).

Implications for Thesis and Valuation

• Use adjusted EBITDA as the primary cash-flow proxy, but discount it for recurring stock-based compensation ($50M in FY25, down from a $195M FY22 spike from CEO grant vesting), restructuring charges (run-rate ~$50–100M/year for cost programs), and license-related amortization (intangibles ex-GW amortizing ~$300–400M/year run rate).
• Free cash flow conversion has averaged ~50% of adj. EBITDA over FY22–FY25, in line with prestige beauty norms but below IPAR (~70%).
• The goodwill + intangibles base is a valuation tail risk, not a base-case concern. The FY25 charge mix did not show a major fresh impairment; current intangible amortization is on schedule.

Objective

Assess earnings quality, balance-sheet conservatism, and the disclosure environment around COTY; run an adversarial sweep for short-seller reports, regulatory actions, and known accounting controversies.

Narrative Analysis

GAAP vs. adjusted earnings reconciliation (FY25)

Item	$M	Notes
Adj. EBITDA (company-reported)	1,084	Per Q4 FY25 release
Less: D&A	(~340)	Mostly intangible amortization
Less: Restructuring + impairment + one-offs	(~503)	Elevated in FY25
GAAP operating income	241.1	[S1]
Less: Interest expense	(~240)	On $4B LT debt
Plus / minus: Equity method (Wella + others) + FX	(~30)	Wella mark-to-market
Less: Tax	(~150)	Effective rate noisy due to mix and impairments
Plus: Discontinued operations / other	varies
GAAP net income (loss)	(367.9)	[S1]

The largest reconciling item between adjusted and GAAP is impairment of intangibles and goodwill from prior periods. The FY25 GAAP net loss of $367.9M reflects an elevated impairment year — the underlying cash earnings story is materially better than the headline net loss suggests.

Earnings quality flags reviewed

Flag	Observation	Verdict
Aggressive revenue recognition	Standard wholesale recognition at shipment; some returns reserve volatility but no significant unusual accruals	No flag
Capitalization of operating costs	Capex ~$170M in FY25 (3% of sales) — modest, not aggressive	No flag
Inventory build vs. sales	Inventory $1.1B at FY25 end (~6.7 months of COGS) — slightly elevated but not extreme; flagged as "elevated E&O" in Q3 FY26 release	Yellow flag — inventory drag noted
Receivables stretch	AR $0.9B at FY25 end (~55 days) — normal	No flag
SBC trend	SBC normalized from FY22 $195.5M peak to FY25 $50.0M	Improving
Tax rate volatility	Tax rate erratic due to international mix and impairment-driven losses	Cosmetic only
Equity-method investment	Wella stake — historically large and variable; now monetized via Dec 2025 sale	Resolved
Working capital quality	DSO + DIO − DPO ~80–90 days; normal for prestige beauty	No flag
Off-balance-sheet	Operating leases capitalized under ASC 842; no off-BS structures of note	No flag
Auditor	Deloitte (long-standing) — no auditor change concerns	No flag
Restatement history	FY19/FY20 restatement driven by Wella deconsolidation accounting (not aggressive)	One-time

Adversarial Research Sweep

This is the mandatory short-seller / litigation / investigation scan. Conducted via web search across the standard sources (Hindenburg, Muddy Waters, Citron, Spruce Point, Wolfpack, GMT Research, Kynikos, Bonitas, Hindenburg Light + general litigation databases).

Vector	Finding	Status
Activist short report	None identified as of May 2026. Coty has not been a target of a major short report.	Clean
Securities-fraud class action	None active and material as of May 2026.	Clean
SEC enforcement	No active SEC enforcement actions disclosed in 10-K	Clean
Insider trading investigation	None	Clean
Talc / personal injury litigation	Industry-wide claims exist; Coty is one of many defendants but not the lead defendant (J&J / Imerys are the lead defendants industry-wide). Coty's potential exposure is well within reserves and not commented as material in 10-K	Yellow but small
PFAS / "forever chemicals" litigation	Industry-wide regulatory uncertainty; not a Coty-specific issue	Yellow but small
Patent / IP claims	Routine industry-standard claims; nothing material	Clean
FCPA / anti-bribery	No public investigations	Clean
Tax controversies	Routine ETR variability from international mix; no major IRS or OECD-level dispute disclosed	Clean
Board / governance	JAB's controlling stake creates structural minority-shareholder risk (related-party transactions historically clean per proxy disclosure)	Yellow structural

Verdict: No material adversarial findings. Coty is structurally low-attention from short-sellers (large float, controlling shareholder, well-known industry, transparent strategic-review process).

Balance sheet quality (FY25 end)

Item	$M	Comment
Cash	257.1	Modest
Receivables (net)	~870	Normal
Inventory	~1,100	Slightly elevated; flagged by mgmt
PP&E (net)	~620	Light-asset model
Equity-method investment (Wella)	~1,000	Sold to KKR Dec 2025 for $750M cash + back-end participation
Goodwill	4,062	Mostly from P&G Beauty 2016
Intangibles ex-GW	3,215	Designer-house licenses + acquired customer relationships
Other	~785
Total assets	11,908
ST debt	~100	Maturity ladder is manageable
LT debt (noncurrent)	3,956	Down from $7.9B in FY20
Operating lease liabilities	~400
AP + accruals	~1,950	Normal
Other	~1,548
Total liabilities	7,952
Stockholders' equity	3,543	Equity has been holding up despite FY25 net loss; OCI movements and SBC are the swing factors

Evidence and Sources

Detail in COTY_financials/xbrl/xbrl_summary.md and COTY_financials/sec_filings/10K_FY2025_summary.md.

Assumption Register Updates

• A09 (Goodwill $4.06B at FY25 end) — Fact, High sensitivity to impairment risk
• A10 (Intangibles ex-GW $3.21B at FY25 end) — Fact, High sensitivity
• A11 (FY25 SBC $50M vs FY22 peak $195.5M) — Fact

Tables and Calculations

Cash flow quality (FY21–FY25)

FY	Adj. EBITDA (approx)	CFO	Capex	FCF (CFO − Capex)	FCF / Adj. EBITDA
2021	~640	318.7	(~140)	~180	~28%
2022	~900	726.6	(~160)	~567	~63%
2023	~1,000	625.7	(~165)	~461	~46%
2024	~1,140	614.6	(~175)	~440	~39%
2025	1,084	492.6	(~170)	~323	~30%

FY25 FCF conversion stepped down vs. prior years on working-capital absorption (inventory build) and lower CFO from operating profit pressure. The Q3 FY26 release flagged inventory destocking as ongoing.

Auditor & control environment

• Auditor: Deloitte & Touche LLP (long tenure)
• Internal control: No material weakness disclosed in FY25 10-K
• Reported restatement history: One restatement in FY19–FY20 tied to Wella deconsolidation accounting (not a quality concern)

Open Questions and Data Gaps

1. Future impairment-test outcome. Tied to discount-rate and free-cash-flow assumptions in the goodwill test. A 100-bps WACC increase could trigger a $500M+ impairment.
2. Working capital trajectory. If inventory normalizes, FCF conversion should recover toward 50–60%.
3. Tax rate normalization. Effective tax rate has been noisy due to mix and impairments; a clean run-rate is hard to anchor.

Next-Step Dependencies

Step 05 deepens the quarterly momentum analysis and produces the KPI sidecar. Step 06 examines the balance sheet + dilution dynamics in more depth. Step 09 will refine the ROIC framework.

Source Index

Tag	Document or URL	Section / Page	Date	Notes
[S1]	COTY_financials/xbrl/xbrl_summary.md	Full P&L + balance sheet	2026-05-28	SEC XBRL
[S2]	COTY_financials/other/consensus.md + Coty Q3 FY26 8-K	Q3 FY26 result detail	2026-05-05	Accession 0001024305-26-000028
[S3]	COTY_financials/sec_filings/10K_FY2025_summary.md	MD&A, impairment, risk factors	2025-08	FY25 10-K
[S4]	COTY_financials/sec_filings/filing_inventory.md	Filings list	2026-05-28	SEC EDGAR
[S5]	COTY_financials/proxy/governance_and_compensation.md	Audit committee + auditor disclosure	2025-09	DEF 14A
[S6]	Web search results — adversarial sweep	Short-report / litigation scan	2026-05-28	No material findings

---

source: coverage-next-full step: 12 type: catalysts_bull_bear ticker: COTY company: Coty Inc. generated: 2026-05-28

Step 12 — Catalysts / Bull vs Bear Debate

Key Findings

• The defining near-term catalyst is the September-2025 strategic review of Consumer Beauty — the binary that converts COTY from a slow-growth conglomerate into either (a) a focused prestige-fragrance pure-play trading nearer to IPAR multiples (~12–14x EV/EBITDA) or (b) an unsuccessful carve-out attempt that resets the equity narrative [S1][S2].
• Bull thesis is structural (fragrance category secular growth, scale + counter-positioning moat, deleveraging completion, dividend reinstatement) rather than a quick-cycle trade. Bear thesis is operational and near-term (mass-color erosion, tariff GM compression, license-renewal binary risk, controlling-shareholder concentration) [S2][S3].
• The debate cannot be resolved on filings alone. Without earnings-call transcript color, the qualitative view of "is management confident?" must be inferred from (a) the Aug-2025 CEO open-market purchase of ~272.5k shares at ~$5.50–6.50, (b) the Q3 FY26 8-K's willingness to raise EPS guidance while lowering EBITDA, and (c) the willingness to put Consumer Beauty under strategic review at all [S4][S5].
• Net: actionable in both directions. The bull case offers a credible path to ~$8–10 over 18–24 months; the bear case implies $2.50–3.00 if the strategic review fails and Prestige weakness extends.

Implications for Thesis and Valuation

• The bull case multiple (12–14x EBITDA) and the bear case multiple (5–6x EBITDA) bracket the entire equity range. Per-share value is enormously sensitive to which case plays out — this is the dispersion that makes COTY an opportunistic position rather than a core holding (see Step 18).
• The Q1 FY27 print (calendar Q3 2026) is the highest-conviction catalyst window: first cleanly post-tariff comparison + first quarter that should reveal strategic-review direction.
• License renewals are the single most important non-modeling discontinuity. The next material renewal events (Marc Jacobs estimated 2027–2030 window; Calvin Klein later) are far enough out to be a watch-item, not a Year-1 forecast input.

Objective

Stage the bull/bear analyst debate around COTY's investment case using the filings-and-consensus path (no transcripts loaded). Identify the catalysts that move the equity in each direction, and end with the 3-bullet bull and 3-bullet bear cases that feed /complete-coverage Step 15 and the public /stocks/{ticker} page.

Narrative Analysis

How the debate sets up without transcripts

Coverage-next-full deliberately excludes earnings-call transcripts. The Step 12 analyst-debate is therefore reconstructed from:

1. 8-K prepared remarks summaries (the press-release portion that includes management quotes and forward-looking commentary) [S3].
2. Consensus notes (analyst expectations, range, and rating distribution) [S4].
3. Recent news flow (Wella divestiture close Dec-2025; KKR full exit Q4-2025; Sept-2025 strategic review announcement) [S2][S5].
4. Insider behavior (Aug-2025 CEO open-market buy is the single strongest signal observed) [S6].

Where the debate would benefit from transcript color (e.g., tone on tariff pass-through, license-renewal confidence, M&A appetite), this step flags the gap rather than fabricating.

The bull case (structural fragrance pure-play)

Pillar	Detail	Source
Strategic-review unlock	Sept 2025 strategic review of Consumer Beauty puts $1.6B of mass-color revenue under explicit evaluation for partnership, divestiture, or spin. A successful divestiture at 1.5x sales (~$2.4B proceeds) would (a) accelerate deleveraging to <2x, (b) lift consolidated GM ~200–400 bps, (c) re-rate the residual fragrance-led business toward IPAR's 12–14x EV/EBITDA multiple from today's ~7x [S1][S2]
Fragrance category tailwind	Global fragrance subsegment growing ~7.4% CAGR through 2031 — fastest-growing major beauty subsegment. COTY is #2 globally with ~$3.7B prestige fragrance scale. Coverage of the winning category is structural [S7] (Step 02 detail)
Deleveraging completion	Net leverage went from 8x (FY20) to 3.2x (FY25) to ~3.0x with Wella proceeds applied. Target 2.0x by CY27. Each turn of deleveraging compresses the equity-risk premium and lifts the implied multiple [S3] (Step 06/07 detail)
CEO insider buy	Aug 2025 open-market purchase of ~272,500 shares at ~$5.50–6.50/share. Sue Nabi has not sold open-market since Sept-2020 hire. This is the strongest single-insider buying signal in years [S6]
Dividend reinstatement	$0.10/year reinstated in FY25 — small in dollar terms but signal-bearing that management views deleveraging as far enough along to return cash. Yield ~2.7% on $3.74 spot. Growth-of-dividend optionality once 2.0x leverage hit [S3]
Wella back-end participation	The Dec-2025 KKR transaction includes 45% back-end participation on Wella's eventual exit. KKR has stated intent to exit Wella within 5–7 years; COTY would receive incremental proceeds — a free option not in consensus [S2]
KKR exit clearing block	KKR fully exited COTY common in late 2025 via final preferred conversion. Removes the largest non-JAB overhang. Index-fund-only float dynamic improves [S2]

The bear case (mass-color erosion + tariff + binary risk)

Pillar	Detail	Source
Consumer Beauty drag persists	Q3 FY26 LFL -10% for Consumer Beauty vs. -5% for Prestige. Mass color cosmetics is in secular share-loss to e.l.f., Charlotte Tilbury masstige, Rare Beauty, and the L'Oréal stable. If the strategic-review fails to find a willing buyer or the buyer demands a steep discount, COTY will be saddled with this drag for several more years [S3][S7] (Step 05 detail)
Tariff GM compression is structural	US tariffs on EU-manufactured prestige fragrance flagged in Q3 FY26 8-K as Q4 driver of -100 to -200 bps GM compression. Estimated $50–100M annualized headwind. If tariff regime persists, this is a permanent cost-base reshape, not a one-quarter event [S3] (Step 11 detail)
License-renewal binary	Coty does not publicly disclose the license-expiry schedule. Market color suggests Marc Jacobs is among the earlier renewals (~2027–2030). The recent loss of Lacoste (to IPAR, 2019) and Roberto Cavalli (to IPAR) shows renewals are not automatic. Losing a top-5 license (e.g., Hugo Boss, Burberry, Calvin Klein, Gucci, Marc Jacobs) would compress EBITDA by ~$100–200M, removing 10–20% of equity value [S8] (Step 10 detail)
Middle East + China travel retail	Q3 FY26 Middle East -140 bps revenue impact; China travel retail volatile through CY24–CY25. These compound into multi-quarter top-line drag [S3] (Step 11 detail)
JAB controlling-stake structural risk	JAB Holdings controls ~50% of Class A → controls board majority. Aligned today, but minority-shareholder protection is structurally lower than at a single-class float. Any change in JAB strategy would have no public-shareholder check [S9] (Step 08 detail)
Heavy goodwill + intangibles	$4.06B goodwill + $3.21B intangibles ex-goodwill = ~$7.3B of soft assets vs. $3.8B equity. Impairment risk is real — the 2019–2020 $5B P&G Beauty cumulative writedowns are the cautionary precedent. Strategic-review divestiture below carry value would trigger fresh impairments [S10] (Step 04/07 detail)
Forecast risk from continued weakness	FY26 EBITDA guide $838–848M vs. FY25 actual $1,084M = -22% YoY. Consensus is below the low end of guide. If FY27 cannot recover, the deleveraging math breaks down [S3] (Step 05 detail)

Catalyst calendar (next 18 months)

Window	Event	Direction	Watch points
Aug 2026	FY26 full-year results + FY27 guide	Tighter post-tariff visibility	First view of Q1 FY27 momentum + initial FY27 framework
Sept 2026	DEF 14A + sustainability filings	Routine	Look for JAB ownership / board composition changes
CY 2026 (any quarter)	Strategic-review outcome announcement	High-impact binary	Announced divestiture multiple; size; cash use
Nov 2026	Q1 FY27 results	First cleanly post-tariff-comparison quarter	LFL inflection; Prestige re-acceleration
Feb 2027	Q2 FY27 results	Holiday quarter momentum	Mass color trajectory if not yet divested
2027	Earliest material license renewal window	Binary	Marc Jacobs renewal terms (if disclosed)
Ongoing	Wella back-end realization	Optional	KKR's Wella-exit timing (likely 5+ years)

What's priced in (from consensus)

Consensus FY26 EPS ~$0.28 vs. company guide $0.33–$0.35; analyst PT range $4–$7 (median $5–$6) on a $3.74 May-2026 spot. This implies:

• Street treats the Q3 FY26 EPS raise with skepticism (consensus below guide).
• Street is pricing in some strategic-review unlock but not the full pure-play re-rate.
• Street is pricing in continued license renewals (no haircut for renewal risk).

The variant view (developed in Step 16) is that Street is under-pricing the strategic-review optionality and over-emphasizing near-term mass-color drag.

The "if I am wrong" lens

Each side of the debate has a clean falsification trigger:

• Bull case falsified if: Consumer Beauty strategic review concludes without a transaction (Dec-2026 or beyond), or a material license is lost at renewal, or tariff regime escalates further.
• Bear case falsified if: Consumer Beauty divestiture lands at ≥1.5x sales, or CEO continues open-market buying through 2026, or Prestige LFL turns clearly positive by Q1 FY27.

Evidence and Sources

Detail in COTY_financials/other/consensus.md, COTY_financials/presentations/investor_presentation_2025.md, COTY_financials/sec_filings/10K_FY2025_summary.md, COTY_financials/proxy/insider_transactions.md, and COTY_financials/industry/market_overview.md. Earnings-call transcripts were intentionally not loaded; management-tone color is sourced from 8-K prepared remarks and press releases only.

Assumption Register Updates

• A27 (Strategic review outcome timing CY2026) — Estimate, High sensitivity
• A28 (License-renewal cycle clustering 1–2 majors per year) — Estimate, High sensitivity

(Both entries already present in COTY_assumption_register.md; no new entries this step.)

Tables and Calculations

Bull / Bear EBITDA fan (rough framing for /complete-coverage Step 15)

Scenario	FY27 EBITDA range	Implied multiple	Implied equity per share	Comment
Bull (Consumer Beauty divested at 1.5x, Prestige recovers 3–5%)	$1,000–1,100M	11–13x EV/EBITDA	~$8–10	Plus dividend + potential Wella back-end
Base (Mid-recovery; some strategic action but not full divestiture)	$850–950M	7–8x EV/EBITDA	~$4.50–5.50	Modest re-rate as deleveraging completes
Bear (Strategic review fails; license loss; tariff persists)	$700–800M	5–6x EV/EBITDA	~$2.50–3.00	Multiple compression overtakes deleveraging benefit

(Approximate framing only. /complete-coverage Step 14 will produce the formal DCF + multiples grid; Step 15 will assign probabilities and an expected value.)

Catalyst probability framing (analyst-debate working hypothesis)

Catalyst	Estimated probability over 18mo	Direction	Magnitude
Consumer Beauty divestiture announced	50%	Bull	+30–60%
Consumer Beauty strategic review extended / no transaction	30%	Neutral-bear	-10–20% (multiple compression)
License loss at renewal	10–15% in any given year	Bear	-15–25% per material loss
FY27 Prestige LFL inflection (positive turn)	60%	Bull	+20–30%
Tariff regime escalation	25%	Bear	-10–15%
Tariff regime de-escalation	25%	Bull	+10–15%
Wella back-end realized within 24 months	15%	Bull	+5–10% (optional upside)
CEO insider sale signal	<5%	Bear	High signal value if it occurred

(Probabilities are working hypotheses for the analyst debate; /complete-coverage Step 15 will refine these into an expected-value scenario tree.)

Open Questions and Data Gaps

1. Management's confidence on Q4 FY26 / FY27 inflection — would benefit from earnings-call transcript color; flagged for /complete-coverage to consider whether re-running with transcripts is warranted.
2. License-renewal calendar — Coty does not publish; market color is the only source.
3. Strategic-review divestiture process — Coty has not disclosed timeline beyond "actively pursuing."

Next-Step Dependencies

Step 16 will sharpen the variant view vs. consensus. Steps 17 and 18 will close out institutional positioning and portfolio sizing. The 3-bullet bull and 3-bullet bear summaries below feed /complete-coverage Step 15 (scenarios) and the public /stocks/{ticker} page.

Source Index

Tag	Document or URL	Section / Page	Date	Notes
[S1]	COTY_financials/presentations/investor_presentation_2025.md	Sept 2025 strategic-review framing	2026-05-28	Coty press releases
[S2]	Coty press release — Coty Sells Remaining Stake in Wella to KKR	Dec 2025 transaction terms	2025-12-19	https://investors.coty.com/news-events-and-presentations/news/news-details/2025/Coty-Sells-Remaining-Stake-in-Wella-to-KKR/default.aspx
[S3]	COTY_financials/other/consensus.md + Coty Q3 FY26 8-K	FY26 guide + Q3 commentary	2026-05-05	Accession 0001024305-26-000028
[S4]	COTY_financials/other/stockanalysis_summary.md	Consensus EPS + analyst PT range	2026-05-28	StockAnalysis.com / WallStreetZen
[S5]	Coty press release — Strategic Review of Consumer Beauty + Brand Reorganization	Sept 2025 announcement	2025-09	Coty.com news
[S6]	COTY_financials/proxy/insider_transactions.md	Aug 2025 CEO buy detail	2026-05-28	SEC Form 4 + GuruFocus
[S7]	COTY_financials/industry/market_overview.md + competitive_landscape.md	Fragrance CAGR + mass-color dynamics	2026-05-28	Mordor Intelligence + Circana 2025
[S8]	Step 10 (this folder)	License durability + Lacoste/Cavalli precedent	2026-05-28	Internal cross-ref
[S9]	COTY_financials/proxy/governance_and_compensation.md	JAB structural board control	2025-09	DEF 14A 0001024305-25-000052
[S10]	COTY_financials/xbrl/xbrl_summary.md + Step 04	Goodwill / intangibles + adversarial sweep	2026-05-28	SEC XBRL

Note: Earnings-call transcripts were intentionally not loaded (coverage-next-full path). Management tone, Q&A color, and forward-looking commentary nuance are not captured here.

Bull Case — 3 bullets

• Strategic-review unlock + multiple re-rate. A Consumer Beauty divestiture at 1.5x sales (~$2.4B proceeds) accelerates deleveraging to <2x, lifts consolidated gross margin 200–400 bps, and re-rates the residual fragrance-led business toward Inter Parfums' 12–14x EV/EBITDA multiple from today's ~7x — a doubling of the equity from a $3.74 base. [S1][S2]
• Fragrance category secular winner + scale moat. Global fragrance is growing ~7.4% CAGR (fastest major beauty subsegment), and COTY is #2 globally with ~$3.7B of prestige fragrance scale. Scale + counter-positioning (designer houses prefer to license operationally complex global distribution) sustain a durable ~250–300 bps ROIC-over-WACC spread. [S7]
• Deleveraging + CEO insider buy + Wella back-end. Net leverage 8x → 3.0x → 2.0x target by CY27; CEO Sue Nabi bought ~272,500 shares open-market in Aug 2025 (no open-market sales since 2020 hire); Wella back-end participation (45% of KKR's eventual exit) is a free option that consensus is not pricing. [S3][S6]

Bear Case — 3 bullets

• Consumer Beauty drag + tariff structural reset. Q3 FY26 Consumer Beauty LFL -10% vs. Prestige -5%; US tariffs on EU-manufactured fragrance flagged as -100 to -200 bps Q4 GM compression (~$50–100M annualized). If the strategic review fails to find a buyer at reasonable multiples and tariff regime persists, COTY is saddled with mass-color erosion plus a permanently higher cost base — bear-case EBITDA $700–800M implies ~$2.50–3.00/share. [S3]
• License-renewal binary risk. COTY does not disclose the license-expiry schedule. Recent renewal-cycle precedents include the loss of Lacoste (to IPAR, 2019) and Roberto Cavalli — renewals are not automatic. Losing a top-5 license (Hugo Boss / Burberry / Calvin Klein / Gucci / Marc Jacobs) would remove ~$100–200M of EBITDA and 10–20% of equity value at once. [S8]
• JAB controlling-stake + impairment overhang. JAB Holdings controls ~50% of Class A and board majority — no public-shareholder check on strategic decisions. $4.06B goodwill + $3.21B intangibles = ~$7.3B of soft assets vs. $3.8B equity, and the 2019–2020 $5B P&G Beauty cumulative writedown precedent is unrebutted. A Consumer Beauty divestiture below carry value would trigger fresh impairments. [S9][S10]